Neurogen

Neurogen is a small molecule drug discovery and development company targeting new drug candidates to improve the lives of patients suffering from pain, insomnia, inflammation, depression, and obesity. Neurogen has generated a portfolio of compelling new drug programs through its fully integrated drug discovery platform, successfully solving complex issues in the discovery of small molecule drugs for valuable targets. Neurogen's Accelerated Intelligent Drug Discovery(AIDD) system, its expertise in cellular functional assays, and its depth in medicinal chemistry are key discriminators in the Company's ability to rapidly and cost-effectively identify new drug candidates. Our strategy is to advance a mix of proprietary drugs independently and, when advantageous, collaborate with world-class pharmaceutical companies during the drug development process to obtain additional resources and to access complementary expertise.

Contact Details: 35 Northeast Industrial Road Branford CT 06405 United States of America Tel: 203 488 8201 Fax: 203 481 8683 Email: edodge@nrgn.com WWW: www.neurogen.com/

Loading...

Recent Publications by Neurogen:
C5a, but not C3a, increases VEGF secretion in ARPE-19 human retinal pigment epithelial cells. PURPOSE: We examined the potential for the pro-inflammatory complement...	7th February, 2009	Neurogen Corporation, Branford,	Curr Eye Res. 2009 Jan;34(1):57-61. DOI Direct Link
Characterization of N-(adamantan-1-ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl)methyl]-2-chloro-ben zamide, a P2X7 antagonist in animal models of pain and inflammation. Recent evidence suggests that the P2X(7) receptor may play a role in the...	6th January, 2009	Department of Pharmacology, Neurogen Corporation, Branford, Connecticut,	J Pharmacol Exp Ther. 2008 Dec;327(3):620-33. Epub 2008 Sep 4. DOI Direct Link
Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-m ethanamine], a novel, orally bioavailable C5a receptor inverse agonist. The complement system represents an innate immune mechanism of host...	6th January, 2009	Department of Molecular Biology and Biochemistry, Neurogen Corporation,	J Pharmacol Exp Ther. 2008 Dec;327(3):898-909. Epub 2008 Aug 27. DOI Direct Link
2-Arylpyrimidines: novel CRF-1 receptor antagonists. The design, synthesis and structure-activity relationship studies of a...	17th December, 2008	Neurogen Corporation, 35 Northeast Industrial Road, Branford, CT 06405,	Bioorg Med Chem Lett. 2008 Aug 15;18(16):4486-90. Epub 2008 Jul 18. DOI Direct Link
Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution. A focused SAR exploration of the lead 4-aminoquinazoline TRPV1 antagonist...	17th December, 2008	Neurogen Corporation, 35 N. E. Industrial Road, Branford, CT 06405, USA.	Bioorg Med Chem Lett. 2008 Aug 15;18(16):4573-7. Epub 2008 Jul 15. DOI Direct Link
→View more Neurogen research publications.

Press Releases on Neurogen:
Former Pfizer Global R&D President John LaMattina Joins PureTech Ventures as Senior Partner; PureTech Announces Partner Promotions	10th November, 2009	PureTech Ventures	BOSTON, Nov. 10 /PRNewswire/ -- PureTech Ventures today announced that John LaMattina, Ph.D., former President, Pfizer Global Research & Development and Executive Vice President, Pfizer, Inc., has

BioNews Results for Neurogen:
Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Pr	Pharma Live:  Nov 13 2009 12:22AM Matching: neurogen
Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Pr	Therapeutics Daily:  Nov 12 2009 1:32PM Matching: neurogen
Pfizer's New London Complex May Be Hard Sell	Hartford Courant:  Nov 12 2009 1:44PM Matching: neurogen
New thoracic outlet syndrome study findings recently were reported by researchers at Massachusetts General Hos	Pharmacy Choice:  Nov 11 2009 3:36PM Matching: neurogen
PureTech Ventures adds ex-Pfizer exec John LaMattina as senior partner	AltAssets.net:  Nov 11 2009 6:28PM Matching: neurogen
Promote your company here: BioNewsCast - Press Release Distribution	→View more Neurogen news.

Neurogen Clinical Trials:
Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

Neurogen Patents:
US Patent No.	Title
6943199	Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines
7074799	Substituted quinazolin-4-ylamine analogues
7074929	Certain alkylene diamine-substituted heterocycles
7078187	Melanin concentrating hormone receptors
7078484	Melanin concentrating hormone receptors
→View more Neurogen patents.

Neurogen (NRGN) Financial information Links from Barchart
NRGN Quote from from Barchart.com
NRGN Chart from from Barchart.com
NRGN Profile from from Barchart.com
NRGN Opinion from from Barchart.com
→View more Neurogen finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 20 individuals from Neurogen using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 598 times since April 2007, the link to the organisation's website has been followed 93 times

Recent Search Terms used to find this page: NDT9513727 | neurogen complement | NDT9513727 structure | neurogen C5a 2009 | NDT 9513727 | NDT-9513727 OR NDT9513727 OR NDT 9513727 | NDT 9513727 | Neurogen C5a | NDT 9513727 | neurogen drug | .

Search for more companies in Branford

Search for more companies in CT

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Neurogen